LG Chem Life Sciences Innovation Center and LabCentral Announce the 2020 Golden Ticket Winner – Mediar Therapeutics – Accelerating Innovative Fibrosis Therapeutics

Oct 30, 2020

October 27, 2020 11:02 AM Eastern Daylight Time

CAMBRIDGE, Mass.–Today, the LG Chem Life Sciences Innovation Center announces that it has selected Mediar Therapeutics as the winner of their inaugural Golden Ticket Program. LabCentral is a first-of-its-kind shared laboratory space designed as a launchpad for high-potential life-sciences and biotech startups located in the heart of Kendall Square in Cambridge, MA. The Golden Ticket will provide Mediar Therapeutics with a voucher for one year of prepaid rent for a reserved bench space for one scientist, including benefits of shared infrastructure and services.

As a LabCentral sponsor, LG Chem Life Sciences Innovation Center can select a qualifying startup company each year to take up residence in LabCentral’s Kendall Square facility through use of the Golden Ticket. LG Chem’s Golden Ticket Program is designed to assist high-potential and innovative early-stage life science and biotech companies.

“The Golden Ticket is an effective way to establish a close connection with innovation and new companies that are working in the Cambridge ecosystem,” said Alex Gaither, Vice President, Translational Medicine at the LG Chem Life Sciences Innovation Center. “We spent several months speaking with numerous companies across LabCentral to finally decide on Mediar. The novel approach Mediar is taking to target fibrosis is quite unique and we are excited to see the progress of their platform over the next year.”

Mediar Therapeutics is a preclinical company focused on developing new anti-fibrotic therapies against a novel class of targets known as “fibrotic mediators.”

“As a seed stage company, we are thrilled to be receiving a Golden Ticket from LG Chem,” said Meredith Fisher, Interim Chief Executive Officer of Mediar Therapeutics. ” LG Chem is a leading company in the development of fibrotic therapies, particularly NASH, which is an indication of strong interest to Mediar.”

“Mediar Therapeutics is pursuing exciting new biology and anti-fibrotic targets which is a great compliment to our internal expertise. We look forward to a fruitful engagement with them as our first Golden Ticket awardee.” said Vice President, Translational Medicine at the LG Chem Life Sciences Innovation Center.


Click here to view source version on businesswire.com

Click here to watch LG Chem Golden Ticket 2020 video


About LG Chem Life Sciences

LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing, as well as commercializing pharmaceutical products globally. LG Chem Life Sciences seeks to expand and make global presence by focusing on key core therapeutic areas of Immunology, Oncology, and Metabolic Diseases (specifically, diabetes and related metabolic diseases). To achieve such, its strategy is to actively pursue global collaboration encompassing from asset-centric to strategic investment and collaboration.

About Mediar Therapeutics

Mediar is a preclinical stage biotechnology company developing therapeutics to halt, or even reverse, fibrosis. The platform and pipeline are based on an emerging class of novel targets – fibrotic mediators – that play key roles in modulating myofibroblast biology and the development of fibrosis in chronically damaged organs. Mediar was co-founded by leading fibrosis researchers from Mass General Brigham and Mass General Brigham Ventures in 2019.



LG Chem Life Sciences Innovation Center
General Inquiries: contact.cbl@lgchem.com
Partners: partners.cbl@lgchem.com
Media (Jiin Chung): media.cbl@lgchem.com

Mediar Therapeutics
Paul Yaworsky: paul@mediartx.com

Lindsay Crockett: lcrockett@labcentral.org

See all Member News